A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents with Advanced NUT Cancer
This is a multicenter, open-label, single-arm, phase II study to evaluate the efficacy, safety, and pharmacokinetics of NHWD-870 HCl in adults and adolescents with advanced NUT cancer.
Advanced Solid Tumor (Phase 1)
DRUG: NHWD-870 HCl
Objective response rate (ORR), Completed at least four weeks of treatment, the curative effect evaluation of CR, PR and maintain at least 4 weeks, the proportion of the subjects,up to 5 months;
Duration of response (DoR), Completed at least four weeks of treatment,first time participants from CR or PR to onset of disease (PD),up to 5 months;|Disease control rate (DCR), Completed at least four weeks of treatment,tumor curative effect evaluation of CR, PR and SD proportion of subjects,up to 5 months;|Progression-free survival (PFS), From start studying drug therapy to the disease progression or any reason for the first time the time of death,up to 12 months;|time to remission (TTR), From the beginning the study drug therapy to ease for the first time (including patients with CR and PR),up to 5 months.
This is a multicenter, open-label, single-arm, phase II study to evaluate the efficacy, safety, and pharmacokinetics of NHWD-870 HCl in adults and adolescents with advanced NUT cancer.